In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-δ,γ inhibitor, in combination with romidepsin or bortezomib in relapsed/refractory T-cell lymphoma Meeting Abstract


Authors: Moskowitz, A. J.; Koch, R.; Mehta-Shah, N.; Myskowski, P.; Kheterpal, M.; Dogan, A.; Davey, T.; Galasso, N.; Evan, M.; Shah, M.; Ganesan, N.; Lubin, L.; Kim, Y. H.; Khodadoust, M.; Almazan, T.; Dai, J.; Jacobsen, E. D.; Weinstock, D. M.; Horwitz, S. M.
Abstract Title: In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-δ,γ inhibitor, in combination with romidepsin or bortezomib in relapsed/refractory T-cell lymphoma
Meeting Title: 59th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 130
Issue: Suppl. 1
Meeting Dates: 2017 Dec 9-12
Meeting Location: Atlanta, GA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2017-12-07
Language: English
ACCESSION: WOS:000432419402069
PROVIDER: wos
Notes: Meeting Abstract: 819 -- Source: Wos
MSK Authors
  1. Steven M Horwitz
    351 Horwitz
  2. Alison Moskowitz
    141 Moskowitz
  3. Patricia Myskowski
    133 Myskowski
  4. Ahmet Dogan
    166 Dogan
  5. Theresa Davey
    2 Davey
  6. Monica Jignesh Shah
    1 Shah
  7. Lakeisha C Lubin
    3 Lubin